Core Viewpoint - The company has received a notice of acceptance from the National Medical Products Administration for its drug HSK39297, a selective complement factor B inhibitor aimed at treating paroxysmal nocturnal hemoglobinuria (PNH) in adult patients who have not previously received complement inhibitors [1][2][3] Group 1: R&D Project Overview - HSK39297 is a self-developed small molecule inhibitor that blocks the activation of the alternative pathway of the complement system, targeting diseases mediated by abnormal complement activation [2] - Clinical research indicates that HSK39297 has good safety and tolerability, showing significant therapeutic advantages over eculizumab in improving anemia, reducing transfusion needs, and alleviating fatigue symptoms [2] - The drug is classified as a Class 1 chemical drug in China and is the first-tier CFB inhibitor for PNH, addressing a significant unmet clinical need with promising market prospects [2] Group 2: Regulatory Approval and Clinical Trials - The application for HSK39297 has been prioritized for review due to its classification as an innovative drug for treating urgent clinical needs and rare diseases [3] - HSK39297 is currently undergoing Phase II clinical trials for lupus nephritis and is set to initiate Phase III clinical research for primary IgA nephropathy [3]

Core Viewpoint - The company announced that its subsidiary, Sichuan Hisun Pharmaceutical Co., Ltd., received a Notice of Acceptance from the National Medical Products Administration for its drug HSK39297, a selective complement factor B inhibitor aimed at treating diseases mediated by abnormal complement activation [1] Group 1 - HSK39297 is a self-developed small molecule inhibitor that effectively inhibits the activity of complement factor B, blocking the activation of the alternative pathway and the complement amplification cycle [1] - The drug is designed to control both C3b-mediated extravascular hemolysis and terminal complement-mediated intravascular hemolysis in patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) [1] - HSK39297 acts at the proximal end of the complement cascade's alternative pathway, targeting the mechanisms that lead to hemolysis [1]

Core Viewpoint - The announcement indicates that the subsidiary Sichuan Haisco Pharmaceutical Co., Ltd. has received a notice from the National Medical Products Administration regarding the acceptance of the drug application for HSK39297, which is aimed at treating adult patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) who have not previously received complement inhibitors [1] Group 1 - HSK39297 is classified as a Class 1 chemical drug according to China's new chemical drug registration classification regulations [1] - The drug is a highly efficient selective complement factor B (FB) small molecule inhibitor developed by the company [1] - HSK39297 works by inhibiting FB activity to block the activation of the alternative pathway (AP) and the complement amplification cycle, thereby suppressing the overall activity of the complement pathway [1]